Pinnacle Associates’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-10,678
| Closed | -$139K | – | 713 |
|
|
2020
Q3 | $139K | Sell |
10,678
-294,505
| -97% | -$3.73M | ﹤0.01% | 656 |
|
|
2020
Q2 | $3.46M | Sell |
305,183
-11,745
| -4% | -$167K | 0.09% | 215 |
|
|
2020
Q1 | $4.54M | Sell |
316,928
-64,673
| -17% | -$1.37M | 0.14% | 165 |
|
|
2019
Q4 | $10.4M | Sell |
381,601
-30,980
| -8% | -$852K | 0.23% | 122 |
|
|
2019
Q3 | $11.8M | Sell |
412,581
-28,157
| -6% | -$820K | 0.28% | 100 |
|
|
2019
Q2 | $12.2M | Sell |
440,738
-39,099
| -8% | -$1.1M | 0.29% | 95 |
|
|
2019
Q1 | $15.9M | Buy |
479,837
+7,200
| +2% | +$219K | 0.36% | 78 |
|
|
2018
Q4 | $13.7M | Sell |
472,637
-24,694
| -5% | -$888K | 0.35% | 80 |
|
|
2018
Q3 | $22.9M | Sell |
497,331
-79,442
| -14% | -$3.53M | 0.47% | 60 |
|
|
2018
Q2 | $21.6M | Sell |
576,773
-102,270
| -15% | -$3.45M | 0.44% | 63 |
|
|
2018
Q1 | $20.1M | Sell |
679,043
-32,444
| -5% | -$1.1M | 0.39% | 73 |
|
|
2017
Q4 | $24.4M | Sell |
711,487
-67,794
| -9% | -$2.29M | 0.47% | 62 |
|
|
2017
Q3 | $28.2M | Sell |
779,281
-21,650
| -3% | -$618K | 0.52% | 58 |
|
|
2017
Q2 | $20.7M | Sell |
800,931
-33,025
| -4% | -$701K | 0.4% | 73 |
|
|
2017
Q1 | $16M | Sell |
833,956
-37,077
| -4% | -$657K | 0.31% | 92 |
|
|
2016
Q4 | $14.5M | Sell |
871,033
-51,703
| -6% | -$935K | 0.29% | 97 |
|
|
2016
Q3 | $19M | Sell |
922,736
-13,440
| -1% | -$341K | 0.38% | 80 |
|
|
2016
Q2 | $28.6M | Sell |
936,176
-13,443
| -1% | -$467K | 0.62% | 41 |
|
|
2016
Q1 | $35.5M | Buy |
949,619
+5,110
| +0.5% | +$193K | 0.76% | 33 |
|
|
2015
Q4 | $40.8M | Sell |
944,509
-58,351
| -6% | -$2.47M | 0.86% | 29 |
|
|
2015
Q3 | $37.6M | Sell |
1,002,860
-28,800
| -3% | -$1.02M | 0.83% | 30 |
|
|
2015
Q2 | $35.1M | Sell |
1,031,660
-30,770
| -3% | -$1.05M | 0.65% | 38 |
|
|
2015
Q1 | $37.6M | Sell |
1,062,430
-4,121
| -0.4% | -$147K | 0.7% | 32 |
|
|
2014
Q4 | $36.3M | Buy |
1,066,551
+52,405
| +5% | +$1.86M | 0.71% | 33 |
|
|
2014
Q3 | $39.1M | Sell |
1,014,146
-42,474
| -4% | -$1.58M | 0.8% | 28 |
|
|
2014
Q2 | $41.1M | Sell |
1,056,620
-66,467
| -6% | -$2.47M | 0.8% | 32 |
|
|
2014
Q1 | $38.4M | Sell |
1,123,087
-49,840
| -4% | -$1.54M | 0.75% | 36 |
|
|
2013
Q4 | $24.6M | Sell |
1,172,927
-29,900
| -2% | -$756K | 0.48% | 58 |
|
|
2013
Q3 | $28.3M | Sell |
1,202,827
-66,029
| -5% | -$1.88M | 0.58% | 41 |
|
|
2013
Q2 | $34.1M | Buy |
+1,268,856
| New | +$36.8M | 0.77% | 34 |
|
Other funds holding MYGN
CCM
GCM
Pinnacle Associates's MYGN Position: Q4 2020 in Review
Pinnacle Associates sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 10,678 shares — an estimated $139K sold.
Pinnacle Associates first reported a position in MYGN in Q2 2013 and held it in 30 quarters. The position peaked at $41.1M in Q2 2014. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.
- Pinnacle Associates reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
- Pinnacle Associates sold 10,678 Myriad Genetics shares in Q4 2020, an estimated $139K.
- Pinnacle Associates first reported a position in Myriad Genetics in Q2 2013 and held it in 30 quarters.
- Pinnacle Associates's Myriad Genetics position peaked at $41.1M in Q2 2014.
- 187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.
Based on Pinnacle Associates's 13F filing for Q4 2020, filed 26 Jan 2021.